Biovest One Step Closer to Cancer Vaccine Approval in Europe

Biovest International, the biopharmaceutical company behind BiovaxID, a personalized therapeutic cancer vaccine for the treatment of non-Hodgkin’s lymphoma, has taken another step closer to European marketing approval following a regulatory meeting with the European Medicines Agency (EMA)

At the meeting, the EMA provided Biovest with guidance along with legal, regulatory, and scientific information to help finalize their pending Marketing Authorization Application (MAA) seeking EU marketing approval for BiovaxID.

While no time frame can be determined with regard to availability in Europe, if approved it will be the first therapeutic cancer vaccine designed for patients with non-Hodgkin's lymphoma.

Additionally, Biovest has appointed David J. States, M.D., Ph.D., to the their Scientific Advisory Board. Educated at Harvard, at the University of California, San Diego and the National Institutes of Health, Dr. States is a systems biologist who helped to established the discipline of bioinformatics. He is board certified in internal medicine and is a Fellow of the American College of Medical Informatics. Dr. States has been involved in the Human Genome Project from the outset of the project and helped to establish the NIH National Center for Biotechnology Information (NCBI).

Source: Biovest

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap